Title: Hepatic Arterial Infusion Chemotherapy plus Regorafenib in Advanced Colorectal
Cancer: A Real-World Retrospective Study
Version: 2 Date: 10 Feb 2022
Reviewer's report:
This article explored the benefits and tolerability of Hepatic arterial infusion chemotherapy
plus regorafenib in advanced colorectal liver metastasis refractory to standard systemic
chemotherapy. Regorafenib combined with Hepatic arterial infusion chemotherapy is an
effective second-line treatment option for treating colorectal cancer patients with liver metastasis
refractory to standard systemic therapy. Their results indicate that the toxicity was tolerable,
and efficacy outcomes in terms of ORR and PFS were comparable to those of previous reports
in which regorafenib combined with hepatic arterial infusion chemotherapy. The notion that
the regorafenib combined with hepatic arterial infusion chemotherapy is feasible and can be
performed safely in patients with mCRC is interesting. However, the data are too weak to support
their conclusion.
1) The content of the paper and Figures 1, 2, 3, and 5 do not match.
2) The number of metastatic organs was not described, which may have a selection bias.
3)There is no description of RAS status or Location.
Title: Hepatic Arterial Infusion Chemotherapy plus Regorafenib in Advanced Colorectal
Cancer: A Real-World Retrospective Study
Version: 2 Date: 10 Feb 2022
Reviewer's report:
This article explored the benefits and tolerability of Hepatic arterial infusion chemotherapy
plus regorafenib in advanced colorectal liver metastasis refractory to standard systemic
chemotherapy. Regorafenib combined with Hepatic arterial infusion chemotherapy is an
effective second-line treatment option for treating colorectal cancer patients with liver metastasis
refractory to standard systemic therapy. Their results indicate that the toxicity was tolerable,
and efficacy outcomes in terms of ORR and PFS were comparable to those of previous reports
in which regorafenib combined with hepatic arterial infusion chemotherapy. The notion that
the regorafenib combined with hepatic arterial infusion chemotherapy is feasible and can be
performed safely in patients with mCRC is interesting. However, the data are too weak to support
their conclusion.
1) The content of the paper and Figures 1, 2, 3, and 5 do not match.
2) The number of metastatic organs was not described, which may have a selection bias.
3)There is no description of RAS status or Location.
Please review this paper.
user
Title: Hepatic Arterial Infusion Chemotherapy plus Regorafenib in Advanced Colorectal
Cancer: A Real-World Retrospective Study
Version: 2 Date: 10 Feb 2022
Reviewer's report:
This article explored the benefits and tolerability of Hepatic arterial infusion chemotherapy
plus regorafenib in advanced colorectal liver metastasis refractory to standard systemic
chemotherapy. Regorafenib combined with Hepatic arterial infusion chemotherapy is an
effective second-line treatment option for treating colorectal cancer patients with liver metastasis
refractory to standard systemic therapy. Their results indicate that the toxicity was tolerable,
and efficacy outcomes in terms of ORR and PFS were comparable to those of previous reports
in which regorafenib combined with hepatic arterial infusion chemotherapy. The notion that
the regorafenib combined with hepatic arterial infusion chemotherapy is feasible and can be
performed safely in patients with mCRC is interesting. However, the data are too weak to support
their conclusion.
1) The content of the paper and Figures 1, 2, 3, and 5 do not match.
2) The number of metastatic organs was not described, which may have a selection bias.
3)There is no description of RAS status or Location.
assistant